Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region

Schizophrenia Bulletin

Volumn 28, Issue 1, 2002, Pages 31-42

  Weissman, Ellen M ^a,b,c  

^a Veterans Administration   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Olanzapine; Polypharmacy; Prescribing patterns; Risperidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; PIRENZEPINE;

ARTICLE; CLINICAL PRACTICE; COMORBIDITY; ENVIRONMENTAL FACTOR; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; UNITED STATES; ADULT; AGED; CLASSIFICATION; DRUG COMBINATION; DRUG UTILIZATION; MALE; MIDDLE AGED; PRESCRIPTION; PSYCHOLOGICAL ASPECT; PUBLIC HOSPITAL; STATISTICS; URBAN POPULATION; VETERAN;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PIRENZEPINE; PRESCRIPTIONS, DRUG; RISPERIDONE; SCHIZOPHRENIA; URBAN POPULATION; VETERANS;

EID: 0035988515     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006924     Document Type: Article

References (61)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
3. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
4. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
5. Jr. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns
6. Comparative efficacy of olanzapine and haloperidol for patients with treatmentresistant schizophrenia
7. Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
8. Using a computer data base to monitor compliance with pharmacotherapeutic guidelines for schizophrenia
9. Interactions between physicians and drug company representatives
10. A randomized doubleblind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
11. Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medications and prescribing styles
12. Addition of risperidone to clozapine therapy in chronically psychotic inpatients
13. The economics of the treatment of schizophrenia
14. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals
15. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
16. Antipsychotic prescribing practices
17. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine
18. Expected incidence of tardive dyskinesia associated with atypical antipsychotics
19. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics
20. Does risperidone improve verbal working memory in treatment resistant schizophrenia?
21. Olanzapine augmentation of clozapine
22. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
23. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
24. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
25. The evolution of the serotonin-dopamine antagonist concept
26. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy
27. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
28. Polypharmacy-in-a-pill: A scientific advance or are we making a virtue of our necessities?
29. Rational and irrational polypharmacy
30. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia
31. Effects of clozapine on cognitive function in schizophrenia
32. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report
33. The Mount Sinai conference on the pharmacotherapy of schizophrenia
34. Risperidone in the treatment of schizophrenia
35. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five year time series forecasts
36. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
37. Risperidone and clozapine combination for the treatment of refractory schizophrenia
38. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients
39. Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals
40. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel group study versus haloperidol
41. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol
42. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation
43. Olanzapine and sulpiride: A preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia
44. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia
45. Cost-effectiveness of clozapine in patients with high and low levels of hospital use
46. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
47. From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs
48. Risperidone, negative symptoms, and cognitive deficits in schizophrenia: An open study
49. Olanzapine versus haloperidol in first-episode psychosis
50. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A doubleblind, placebo-controlled study
51. Clozapine in tardive dyskinesia: Observations from human and animal model studies
52. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
53. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
54. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders
55. The pharmacoeconomics of antipsychotic medications
56. Novel antipsychotics and new onset diabetes